Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat.
Journal: EClinicalMedicine
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Zaitoon H, Abdul-Ghani M, DeFronzo RA (2026). "Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat.". EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104258